NYX‐458 Improves Cognitive Performance in a Primate Parkinson's Disease Model

202031 citationsJournal Article

Authors

A Barth · Aptinyx (United States)

Jay S. Schneider · Thomas Jefferson University

Tom H. Johnston · Atuka (Canada)

Michael P. Hill · Atuka (Canada)

Jonathan M. Brotchie · Atuka (Canada)

Joseph R. Moskal · Northwestern University

Cassia N. Cearley

Abstract

NYX-458 provides benefit in specific domains known to be impaired in PD in a dopamine depletion model of PD-like cognitive impairment. These data support the continued evaluation of NYX-458 as a potential therapeutic for cognitive decline in PD. © 2020 International Parkinson and Movement Disorder Society.

Topics & Keywords

Parkinson's Disease Mechanisms and Treatments Neurological disorders and treatments Neuroscience and Neuropharmacology Research

UN Sustainable Development Goals

Peace, Justice and strong institutions

Publication Details

Published in: Movement Disorders

Volume 35, Issue 4, pp. 640-649

DOI: 10.1002/mds.27962

Field-Weighted Citation Impact: 2.13